Table 2.
Impact of concomitant peripheral arthritis on the treatments received during the 5-year follow-up period in patients with recent onset axial spondyloarthritis
| Any arthritis n = 255 (%) |
No arthritis n = 453 (%) |
p value* | |
|---|---|---|---|
| NSAIDs ever | 246 (96.5) | 435 (96.0) | 0.682 |
| TNFb ever | 126 (49.4) | 132 (29.1) | < 0.001 |
| csDMARDs ever | 103 (40.4) | 63 (13.9) | < 0.001 |
| Oral corticosteroids ever | 96 (37.6) | 100 (22.1) | < 0.001 |
| Intramuscular corticosteroids ever | 6 (2.4) | 3 (0.7) | 0.039 |
| Intravenous corticosteroids ever | 7 (2.7) | 7 (1.5) | 0.336 |
| Intraarticular corticosteroid ever | 79 (31.0) | 31 (6.8) | < 0.001 |
All results are presented as n (%). Percentages indicate number of patients with the covariate from the total number of patients in each category
TNFb TNF blockers, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs
*p value for mixed model with random effects